A Phase III Double-Blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Characterized by PTEN deficiency (CAPItello-281) Principal Investigator: Dr. Eric Batts For more information on this trial, read its profile on clinicaltrials.gov here.
Clinical Trial Type: GI/GU
AstraZeneca PANCAN
A Phase II Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of AZD0171 in Combination with Durvalumab and Chemotherapy in Participants with Locally Advanced or Metastatic Solid Tumours PI: Dr. Chandana Available at: CHCWM – Muskegon, Holland Cancer Center, Lacks Cancer Center at Saint Mary’s, Lemmen-Holton Cancer Pavilion For more information on this
KL264-01 (Klus)
Merck (MK-6482-011)
An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy Principal Investigator: Dr. Sreenivasa Chandana For more information on this trial, read its profile on clinicaltrials.gov here.
Merck MK-6482-012
An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Belzutifan (MK-6482) and Lenvatinib (MK-7902), or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First-line Treatment in Participants with Advanced Clear Cell Renal Cell Carcinoma (ccRCC) Principal Investigator: Dr. Sreenivasa Chandana For more information on this
Sym024-01 (Symphogen)
Description: A Phase 1, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of Sym024 (Anti-CD73) as Monotherapy and in Combination with Sym021 (Anti-PD-1) in Patients with Advanced Solid Tumor Malignancies Target Patient Population: NSCLC (Adeno), Pancreatic, Cholangiocarcinoma, Metastatic Colorectal, Gastric, Esophageal, Mesothelioma and Squamous cell Head & Neck Study Design: Both Drugs
Zymeworks (ZWI-ZW25-201)
A Phase 2 Study of ZW25 Plus First-Line Combination Chemotherapy in HER2-Expression Gastrointestinal (GI) Cancers, Including Gastroesophageal Adenocarcinoma (GEA), Biliary tract Cancer (BTC), and Colorectal Cancer (CRC) Principal Investigator: Dr. Sreenivasa Chandana For more information on this trial, read its profile on clinicaltrials.gov here.